Table 2 Details of the drug targeting epigenetic modifiers in endothelial cells
Name of the drug | Epigenetic enzyme altered by the drug | Status of the clinical study/disease or condition |
|---|---|---|
Trichostatin A | Inhibits class I and II HDAC enzymes | Clinical trial-completed (NCT03838926)/Relapsed or Refractory Hematologic Malignancies |
Valproic acid/VPA | Inhibits class I and class IIa HDACs | Clinical trial-completed (NCT01233609)/ Retinitis Pigmentosa |
Sodium butyrate/NaB | Inhibits class I and class IIa HDACs | Clinical trial-completed NCT00800930/ Shigellosis |
Suberoylanilide hydroxamic acid/SAHA/Vorinostat | Inhibits class I and II HDACs | Clinical trial-completed (NCT00106626)/ Advanced Cancer |
3-Deazaneplanocin-A /DZNep | Inhibits EZH2 methyltransferase | – |
Methylthioadenosine/MTA | Inhibits H3K4 methylase | Clinical trial-completed (NCT03083015)/ Necrotic Pulp |
Morpholino | Inhibits histone acetyltransferase 7/KAT7 | Clinical trial-completed (NCT03375255)/ Muscular Dystrophy, Duchenne |
Resveratrol/RV | Activates sirtuin1/Sirt1 | Clinical trial-completed (NCT01010009)/ Cognitive and Cerebral Blood Flow Effects of Resveratrol |
Panobinostat/LBH589 | Inhibits ClssI, II, and IV HDACs | Clinical trial-completed (NCT00840346)/ Acute Myeloblastic Leukaemia |
Entinostat/SNDX-275/MS 27–275 | Inhibits HDAC1/3 | Clinical trial- completed (NCT02897778)/Cardiac Safety Study With Advanced Solid Tumors |
Mocetinostat | Inhibits HDAC1 and HDAC2 | Clinical trial-completed (NCT02303262)/ Metastatic Leiomyosarcoma |
Lithium | Inhibits GSK3b | Clinical trial-completed (NCT01259388)/ Progressive Multiple Sclerosis |
5-Aza-2′-deoxycytidine (5-dAzaC) | Inhibits DNMT | Clinical trial-completed (NCT00744757)/ Myelodysplastic Syndrome |
GSK2879552 | Inhibits LSD1 | Terminated clinical trials Relapsed/Refractory Small Cell Lung Carcinoma |
Tazemetostat | Inhibits EZH2 (PRC2 subunit) | Clinical trial-completed (NCT02860286)/ Relapsed or Refractory Malignant Mesothelioma |